

Press release for immediate release

Genomtec has filed a patent application for a set of primers for detecting *Salmonella enterica* infections, one of the most common infectious diseases among humans and animals

Wrocław, Poland - August 24, 2021. - Genomtec S.A. "GMT", a NewConnect-listed medical technology company with applications in rapid genetic testing for point-of-care clinical diagnostics, has filed a patent application for a proprietary primer set, diagnostic method and reaction mixture composition for genetic diagnosis of *Salmonella enterica* infections using the LAMP technique. The application was filed with the Patent Office of the Republic of Poland. The detection technology developed by Genomtec is faster and less expensive than those currently used on the market.

Salmonellosis or food poisoning is one of the most common infectious diseases - in both humans and animals. Animals and animal products are considered as a major source of Salmonella. All Salmonella infections begin with ingestion with contaminated food, milk or water and in humans can present as acute gastroenteritis, enteric fever (typhoid fever or paradurium) or bacteremia with or without clinical signs. The vast majority of human cases of salmonellosis disease is caused by bacteria belonging to the species *Salmonella enterica*, which would be now possible to detect through fast and cheaper testing method with the Genomtec® Salmonella Laboratory Kit.

- Applying for patent protection is due to significantly improved diagnostic parameters of our solutions in the area of molecular biology. Moreover, they are characterized by a shorter time needed to obtain a result, which is crucial where fast and very precise diagnostics is required. - said Miron Tokarski, CEO and co-founder of Genomtec.

Patent protection of the technology or processes constituting the given technology is a key area of building and safeguarding the intellectual value developed by Genomtec. Company's technology is being ringfenced by securing ever-increasing number of patents and patent applications for the Genomtec ID diagnostic platform as well as in the space of molecular biology such as this filled application.

#####

Additional information available at:

Genomtec S.A.

Magdalena Kicińska

+48 604 201 230

m.kicinska@genomtec.com



About Genomtec S.A.

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wroclaw.

More information at: www.genomtec.com